Roland Reitsamer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Roland Reitsamer has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Felix Sedlmayer
Department of Radiation Oncology, Paracelsus Medical University, SALK, A-5020 Salzburg, Austria
6 shared publications Florentia Peintinger
Institute of Pathology Medical University of Graz Graz Austria
6 shared publicationsChristian Menzel
Paracelsus Medical University
4 shared publications- Gerd Fastner
Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria
4 shared publications - Wolfgang Hitzl
Research Office (Biostatistics), Paracelsus Medical University, Müllner Hauptstrasse 48, 5020 Salzburg, Austria
4 shared publications - Franz Zehentmayr
Department of Radiation Oncology, Paracelsus Medical University, A-5020 Salzburg, Austria
3 shared publications
Latest Publications
- Open Access
Cone-Beam CT Segmentation for Intraoperative Electron Radiotherapy Based on U-Net Variants with Transformer and Extended LSTM Approaches
Artificial Intelligence (AI) applications are increasingly prevalent in radiotherapy, including commercial software solutions for automatic segmentation of anatomical structures for 3D Computed Tomography (CT). However, their use in intraoperative electron radiotherapy (IOERT) remains limited. In particular, no AI solution is available for contouring cone beam CT (CBCT) images acquired with a mobile CBCT device. The U-Net convolutional neural network architecture has gained huge success for medical image segmentation but still has difficulties capturing the global context. To increase the accuracy in CBCT segmentation for IOERT, three different AI architectures were trained and evaluated. The features of the natural language processing models Transformer and xLSTM were added to the popular U-Net architecture and compared with the standard U-Net and manual segmentation performance. These networks were trained and tested using 55 CBCT scans obtained from breast cancer patients undergoing IOERT in the department of radiotherapy and radiation oncology in Salzburg, and each architecture’s segmentation performance was assessed using the dice coefficient (DSC) as a similarity measure. The average DSC values were 0.83 for the standard U-Net, 0.88 for the U-Net with transformer features, and 0.66 for the U-Net with xLSTM. The hybrid U-Net architecture, including Transformer features, achieved the best segmentation accuracy, demonstrating an improvement of 5% on average over the standard U-Net, while the U-Net with xLSTM showed inferior performance compared to the standard U-Net. With the help of automatic contouring, synthetic CT images can be generated, and IOERT challenges related to the time-consuming nature of 3D image-based treatment planning can be addressed.
Open AccessCone-Beam CT Segmentation for Intraoperative Electron Radiotherapy Based on U-Net Variants with Transformer and Extended LSTM Approaches
Artificial Intelligence (AI) applications are increasingly prevalent in radiotherapy, including commercial software solutions for automatic segmentation of anatomical structures for 3D Computed Tomography (CT). However, their use in intraoperative electron radiotherapy (IOERT) remains limited. In particular, no AI solution is available for contouring cone beam CT (CBCT) images acquired with a mobile CBCT device. The U-Net convolutional neural network architecture has gained huge success for medical image segmentation but still has difficulties capturing the global context. To increase the accuracy in CBCT segmentation for IOERT, three different AI architectures were trained and evaluated. The features of the natural language processing models Transformer and xLSTM were added to the popular U-Net architecture and compared with the standard U-Net and manual segmentation performance. These networks were trained and tested using 55 CBCT scans obtained from breast cancer patients undergoing IOERT in the department of radiotherapy and radiation oncology in Salzburg, and each architecture’s segmentation performance was assessed using the dice coefficient (DSC) as a similarity measure. The average DSC values were 0.83 for the standard U-Net, 0.88 for the U-Net with transformer features, and 0.66 for the U-Net with xLSTM. The hybrid U-Net architecture, including Transformer features, achieved the best segmentation accuracy, demonstrating an improvement of 5% on average over the standard U-Net, while the U-Net with xLSTM showed inferior performance compared to the standard U-Net. With the help of automatic contouring, synthetic CT images can be generated, and IOERT challenges related to the time-consuming nature of 3D image-based treatment planning can be addressed.
- 1 June 2023
- Published by Springer Nature
- p. 111-119
Prepectoral Implant-Based Breast Reconstruction with Anterior Implant Coverage
- 1 June 2023
- Published by Springer Nature
- p. 111-119
Prepectoral Implant-Based Breast Reconstruction with Anterior Implant Coverage
- Open Access
- 3 April 2023
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 135 (17-18) , 463-471
Axillary lymph node status and invasive lobular breast cancer
Summary: Background: Invasive lobular carcinoma (ILC) represents the second most common type of invasive breast cancer (BC). Although ILC generally have good prognostic properties (positive estrogen receptor, ER, low tumor grade), they are generally diagnosed at a more advanced stage. The data on the axillary lymph node status in ILC compared to invasive ductal carcinoma (IDC) are considered controversial. Therefore, the aim of this study was to compare the pathological node stage (pN) between ILC and IDC in an Austria-wide register. Methods: Data of the Clinical Tumor Register (Klinisches TumorRegister, KTR) of the Austrian Association for Gynecological Oncology (AGO) were retrospectively analyzed. Patients with primary early BC, invasive lobular or ductal, diagnosed between January 2014 and December 2018, and primary surgery were included. A total of 2127 tumors were evaluated and compared in 2 groups, ILC n = 303, IDC n = 1824. Results: A total of 2095 patients were analyzed in the study. In the multivariate analysis, pN2 and pN3 were observed significantly more frequently in ILC compared with IDC (odds ratio, OR 1.93; 95% confidence interval, CI 1.19–3.14; p = 0.008 and OR 3.22; 95% CI: 1.47–7.03; p = 0.003; respectively). Other factors associated with ILC were tumor grades 2 and 3, positive ER, and pathological tumor stage (pT) 2 and pT3. In contrast, concomitant ductal carcinoma in situ, overexpression of the human epidermal growth factor receptor 2 (HER2), and a moderate and high proliferation rate (Ki67) were found less frequently in ILC. Conclusion: The data show an increased risk of extensive axillary lymph node metastasis (pN2/3) in ILC.
- 3 April 2023
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 135 (17-18) , 463-471
Open AccessAxillary lymph node status and invasive lobular breast cancer
Summary: Background: Invasive lobular carcinoma (ILC) represents the second most common type of invasive breast cancer (BC). Although ILC generally have good prognostic properties (positive estrogen receptor, ER, low tumor grade), they are generally diagnosed at a more advanced stage. The data on the axillary lymph node status in ILC compared to invasive ductal carcinoma (IDC) are considered controversial. Therefore, the aim of this study was to compare the pathological node stage (pN) between ILC and IDC in an Austria-wide register. Methods: Data of the Clinical Tumor Register (Klinisches TumorRegister, KTR) of the Austrian Association for Gynecological Oncology (AGO) were retrospectively analyzed. Patients with primary early BC, invasive lobular or ductal, diagnosed between January 2014 and December 2018, and primary surgery were included. A total of 2127 tumors were evaluated and compared in 2 groups, ILC n = 303, IDC n = 1824. Results: A total of 2095 patients were analyzed in the study. In the multivariate analysis, pN2 and pN3 were observed significantly more frequently in ILC compared with IDC (odds ratio, OR 1.93; 95% confidence interval, CI 1.19–3.14; p = 0.008 and OR 3.22; 95% CI: 1.47–7.03; p = 0.003; respectively). Other factors associated with ILC were tumor grades 2 and 3, positive ER, and pathological tumor stage (pT) 2 and pT3. In contrast, concomitant ductal carcinoma in situ, overexpression of the human epidermal growth factor receptor 2 (HER2), and a moderate and high proliferation rate (Ki67) were found less frequently in ILC. Conclusion: The data show an increased risk of extensive axillary lymph node metastasis (pN2/3) in ILC.
- Open Access
Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)
Background and purpose: To investigate intraoperative electron radiation therapy (IOERT) as a tumor bed boost during breast conserving surgery (BCS) followed by hypofractionated whole breast irradiation (HWBI) on age-correlated in-breast recurrence (IBR) rates in patients with low- to high-risk invasive breast cancer. Material and methods: BCS and IOERT (11.1 Gy) preceded a HWBI (40.5 Gy) in 15 fractions. Five-year IBR-rates were compared by a sequential ratio test (SQRT) with best evidences in three age groups (35–40 y and 41–50 y: 3.6%, >50 y: 2%) in a prospective single arm design. Null hypothesis (H0) was defined to undershoot these benchmarks for proof of superiority. Results: Of 1445 enrolled patients, 326 met exclusion criteria, leaving 1119 as eligible for analysis. After a median follow-up of 50 months (range 0.7–104), we detected two local recurrences, both in the age group >50 y. With no observed IBR, superiority was demonstrated for the patient groups 41–50 and >50 y, respectively. For the youngest group (35–40 y), no appropriate statistical evaluation was yet possible due to insufficient recruitment. Conclusions: In terms of five-year IBR-rates, Boost-IOERT followed by HWBI has been demonstrated to be superior in patients older than 50 and in the age group 41–50 when compared to best published evidence until 2010.
Open AccessHypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459)
Background and purpose: To investigate intraoperative electron radiation therapy (IOERT) as a tumor bed boost during breast conserving surgery (BCS) followed by hypofractionated whole breast irradiation (HWBI) on age-correlated in-breast recurrence (IBR) rates in patients with low- to high-risk invasive breast cancer. Material and methods: BCS and IOERT (11.1 Gy) preceded a HWBI (40.5 Gy) in 15 fractions. Five-year IBR-rates were compared by a sequential ratio test (SQRT) with best evidences in three age groups (35–40 y and 41–50 y: 3.6%, >50 y: 2%) in a prospective single arm design. Null hypothesis (H0) was defined to undershoot these benchmarks for proof of superiority. Results: Of 1445 enrolled patients, 326 met exclusion criteria, leaving 1119 as eligible for analysis. After a median follow-up of 50 months (range 0.7–104), we detected two local recurrences, both in the age group >50 y. With no observed IBR, superiority was demonstrated for the patient groups 41–50 and >50 y, respectively. For the youngest group (35–40 y), no appropriate statistical evaluation was yet possible due to insufficient recruitment. Conclusions: In terms of five-year IBR-rates, Boost-IOERT followed by HWBI has been demonstrated to be superior in patients older than 50 and in the age group 41–50 when compared to best published evidence until 2010.
- 1 October 2021
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 197 (11) , 1032-1036
Intraoperative Teilbrustbestrahlung mit Elektronen (ELIOT) vs. konventionelle Ganzbrustbestrahlung beim invasiven Mammakarzinom im frühen Stadium nach brusterhaltender Operation: Langzeitdaten einer kontrollierten, randomisierten Studie
- 1 October 2021
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 197 (11) , 1032-1036
Intraoperative Teilbrustbestrahlung mit Elektronen (ELIOT) vs. konventionelle Ganzbrustbestrahlung beim invasiven Mammakarzinom im frühen Stadium nach brusterhaltender Operation: Langzeitdaten einer kontrollierten, randomisierten Studie
- Open Access
- 1 June 2021
- Published by Elsevier in The Breast
- Vol. 57, 113-117
The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
- 1 June 2021
- Published by Elsevier in The Breast
- Vol. 57, 113-117
Open AccessThe applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
- 22 April 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 123 (8) , 1845
The iBAG study—a milestone?
- 22 April 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 123 (8) , 1845
The iBAG study—a milestone?
- Open Access
Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
Background: In order to characterize the various subtypes of breast cancer more precisely and improve patients selection for breast conserving therapy (BCT), molecular profiling has gained importance over the past two decades. MicroRNAs, which are small non-coding RNAs, can potentially regulate numerous downstream target molecules and thereby interfere in carcinogenesis and treatment response via multiple pathways. The aim of the current two-phase study was to investigate whether hsa-miR-375-signaling through RASD1 could predict local control (LC) in early breast cancer. Results: The patient and treatment characteristics of 81 individuals were similarly distributed between relapse (n = 27) and control groups (n = 54). In the pilot phase, the primary tumors of 28 patients were analyzed with microarray technology. Of the more than 70,000 genes on the chip, 104 potential hsa-miR-375 target molecules were found to have a lower expression level in relapse patients compared to controls (p-value < 0.2). For RASD1, a hsa-miR-375 binding site was predicted by an in silico search in five mRNA-miRNA databases and mechanistically proven in previous pre-clinical studies. Its expression levels were markedly lower in relapse patients than in controls (p-value of 0.058). In a second phase, this finding could be validated in an independent set of 53 patients using ddPCR. Patients with enhanced levels of hsa-miR-375 compared to RASD1 had a higher probability of local relapse than those with the inverse expression pattern of the two markers (log-rank test, p-value = 0.069). Conclusion: This two-phase study demonstrates that hsa-miR-375/RASD1 signaling is able to predict local control in early breast cancer patients, which—to our knowledge—is the first clinical report on a miR combined with one of its downstream target proteins predicting LC in breast cancer.
Open AccessHsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
Background: In order to characterize the various subtypes of breast cancer more precisely and improve patients selection for breast conserving therapy (BCT), molecular profiling has gained importance over the past two decades. MicroRNAs, which are small non-coding RNAs, can potentially regulate numerous downstream target molecules and thereby interfere in carcinogenesis and treatment response via multiple pathways. The aim of the current two-phase study was to investigate whether hsa-miR-375-signaling through RASD1 could predict local control (LC) in early breast cancer. Results: The patient and treatment characteristics of 81 individuals were similarly distributed between relapse (n = 27) and control groups (n = 54). In the pilot phase, the primary tumors of 28 patients were analyzed with microarray technology. Of the more than 70,000 genes on the chip, 104 potential hsa-miR-375 target molecules were found to have a lower expression level in relapse patients compared to controls (p-value < 0.2). For RASD1, a hsa-miR-375 binding site was predicted by an in silico search in five mRNA-miRNA databases and mechanistically proven in previous pre-clinical studies. Its expression levels were markedly lower in relapse patients than in controls (p-value of 0.058). In a second phase, this finding could be validated in an independent set of 53 patients using ddPCR. Patients with enhanced levels of hsa-miR-375 compared to RASD1 had a higher probability of local relapse than those with the inverse expression pattern of the two markers (log-rank test, p-value = 0.069). Conclusion: This two-phase study demonstrates that hsa-miR-375/RASD1 signaling is able to predict local control in early breast cancer patients, which—to our knowledge—is the first clinical report on a miR combined with one of its downstream target proteins predicting LC in breast cancer.
- 1 December 2019
- Published by Elsevier in The Breast
- Vol. 48, 32-37
Prepectoral direct-to-implant breast reconstruction with complete ADM or synthetic mesh coverage – 36-Months follow-up in 200 reconstructed breasts
- 1 December 2019
- Published by Elsevier in The Breast
- Vol. 48, 32-37
Prepectoral direct-to-implant breast reconstruction with complete ADM or synthetic mesh coverage – 36-Months follow-up in 200 reconstructed breasts
- Open Access
- 19 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-7
Intraoperative radiotherapy (IORT) as boost in breast cancer
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic treatment for locally advanced tumors. Even there, long term (>5y) local tumor control rates mostly beyond 95% were maintained. Compared to other boost methods, an intraoperative treatment has evident advantages in terms of precision (by avoiding a “spatial and/or temporal miss”), cosmetic outcome and patient comfort. Direct visualisation of a tumor bed during surgery guarantees for an accurate dose delivery, which has additionally gained importance in times of primary reconstruction techniques after lumpectomy, since IORT is performed before breast tissue including parts of the tumor bed is mobilized for plastic purposes. As a consequence of direct tissue exposure without distension by hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect on late tissue tolerance and, hence, cosmetic appearance. Boost IORT marginally prolongs the surgical procedure, while significantly shortening postoperative radiotherapy. Its combination with external beam radiotherapy to the whole breast (WBI) is currently tested in two multicentric prospective trials: as kV-IORT in the multicentric TARGIT-B (oost) study, and as IOERT in the HIOB trial (3 weeks hypofractionated WBI preceded by IORT electron boost).
- 19 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-7
Open AccessIntraoperative radiotherapy (IORT) as boost in breast cancer
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI) originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic treatment for locally advanced tumors. Even there, long term (>5y) local tumor control rates mostly beyond 95% were maintained. Compared to other boost methods, an intraoperative treatment has evident advantages in terms of precision (by avoiding a “spatial and/or temporal miss”), cosmetic outcome and patient comfort. Direct visualisation of a tumor bed during surgery guarantees for an accurate dose delivery, which has additionally gained importance in times of primary reconstruction techniques after lumpectomy, since IORT is performed before breast tissue including parts of the tumor bed is mobilized for plastic purposes. As a consequence of direct tissue exposure without distension by hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect on late tissue tolerance and, hence, cosmetic appearance. Boost IORT marginally prolongs the surgical procedure, while significantly shortening postoperative radiotherapy. Its combination with external beam radiotherapy to the whole breast (WBI) is currently tested in two multicentric prospective trials: as kV-IORT in the multicentric TARGIT-B (oost) study, and as IOERT in the HIOB trial (3 weeks hypofractionated WBI preceded by IORT electron boost).